Related Experiment Video

Updated: Jul 9, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Cardiovascular risk and risk management in HIV-infected patients

Oluwatoyin Adeyemi1

  • 1Rush Medical College, Chicago, IL, USA.

Topics in HIV Medicine : a Publication of the International AIDS Society, USA
|December 13, 2007
PubMed

Insights

Patients with human immunodeficiency virus (HIV) face cardiovascular disease risks from common factors and HIV treatment. Management involves addressing risks before and during therapy, prioritizing virologic control for better outcomes.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Patients with human immunodeficiency virus (HIV) share cardiovascular disease (CVD) risk factors with the general population, including smoking, dyslipidemia, hypertension, obesity, and diabetes.
  • HIV infection and its treatment with antiretroviral therapy (ART) introduce additional cardiovascular risks.
  • Existing data suggest a low and decreasing incidence of myocardial infarction (MI) in the HIV-infected population.

Observation:

  • Cardiovascular risk assessment and management should be integrated into routine care for HIV-infected individuals.
  • Interventions to modify metabolic risk factors should be individualized.
  • Virologic control is paramount in managing HIV-infected patients with cardiovascular risk.

Findings:

  • While traditional risk factors contribute, HIV and ART present unique challenges to cardiovascular health.
  • The declining rate of myocardial infarction indicates potential improvements in management or treatment efficacy.
  • Proactive management strategies are crucial for mitigating cardiovascular risks in this population.

Implications:

  • Early and continuous cardiovascular risk assessment is essential for HIV patients.
  • Treatment decisions, including ART initiation and modification, must balance virologic goals with cardiovascular risk.
  • A comprehensive approach to HIV care must address both infectious disease and cardiovascular comorbidities.

More Related Videos

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...